• Latest Posts

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Biotechs outperformed in the top 40 European Tech Companies

Genzyme joins the never-ending list of Ablynx’ partners

Ablynx gets tangled up in partnerships with Big Pharma companies

ADVERTISEMENT

Ablynx gain €2.1m to develop a novel Nanobodies for Ocular applications

ADVERTISEMENT